



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

- Name of Inspector from whom received : Lalruatdika Varte, Drugs Inspector
Drugs Inspector
Office of the Chief Medical Officer, Kolasib, Mizoram-
796082
- Serial No. and date of Inspector's memorandum : 004/IPA-KLB/III-25, 10-JUN-2025
- Number of Sample : 004/IPA-KLB/III-25
- Date of receipt : 26-JUN-2025
- Names of drugs purporting to be contained in the sample : Amlodipine Tablets I.P. (5 mg.)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2025-GUW/LS/2025-26/0610	26/617	ALDT-1008	Jul-2024 Jun-2026	NA	WINGS BIOTECH, 43 And 44, HPSIDC, Industrial Area, Baddi-173 205 (H.P.)

6. Condition of seals on : Seals were intact & identical to the specimen impression of the seal received from Drugs Inspector
[the packet or on portion of sample or container]

7. Result of test or analysis with protocols or test or analysis applied : Please see below
Date of Testing : From 11-Jul-2025 To 08-Aug-2025

COMPOSITION : Each uncoated tablet contains: Amlodipine Besylate I.P. equivalent to Amlodipine 5 mg.

Protocol Applied : I.P.2022

Sr No.	Test Name	Result	Limits
1	Description	White, round, flat, scored on one surface, uncoated tablets, in blister pack.	NA
2	Identification	Gives positive test for Amlodipine Besylate.	NA
3	Average weight	0.1197 g	NA
4	Dissolution	Complies.	NLT 75 % of claim

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
1	Amlodipine	4.81 mg/Tablet	5 mg/Tablet	96.2	90 % to 110 %	I.P.2022

In the opinion of the undersigned the sample referred to above is of **standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P.2022 in respect of test performed.

Date: 26-AUG-2025

Rinku Kalita
GOVERNMENT ANALYST

Rinku Kalita
Government Analyst
T.L., Guwahati-77

-----END OF REPORT-----

